Clarametyx
Developer of biologic therapies and vaccines for biofilm-related chronic bacterial infections
Funding snapshot
About
Clarametyx Biosciences has developed biologic therapies and vaccines for biofilm-related bacterial infections affecting the respiratory tracts. The company has developed its lead product CMTX-001, an immune-enabling antibody therapy, to treat hospital-acquired pneumonia (preclinical development stage). It is also developing therapies for cystic fibrosis, sinusitis, and post-tympanostomy tube otorrhea.
Latest news
No articles yet.
Similar startups
NovaHealth AI
Clinical documentation copilot for ambulatory care networks in the US.
Statiq
Manufacturer of electric vehicle charging hardware and operator of networks
Spyne.ai
Platform offering AI-powered imaging for vehicle photography
Immuneel
Developer of T-cell therapies for the treatment of cancer